2181390 is referenced by 66 patents.
A medicinally active formulation contains i) at least three compounds selected from the group consisting of egg phosphatidylcholine, dilauryl phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, dimyristoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, dimyristoyl phosphatidic acid, dipalmitoyl phosphatidic acid, dipalmitoyl phosphatidylethanolamine, distearoyl phosphatidylcholine, brain phosphatidylserine, brain sphingomyelin, cholesterol, cardiolipin, trioctanoin, triolein, soy phosphatidylcholine, poly(adenylic acid), phosphatidylethanolamine, phosphatidyl glycerol, phosphatidyl inositol, sphingosine, cerebroside (glycolipid), and ii) at least one biodegradable polymer selected from the group consisting of copolymers of sucrose and epichlorohydrin having molecular weights of from 70 000 to 400 000, glucose polymers having molecular weights of from 10 000 to 300 000, polyethylene glycols having molecular weights of from 1000 to 100 000, polyvinyl alcohols having molecular weights of from 70 000 to 110 000, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, hydroxypropyl-ethyl cellulose, sodium carboxymethyl cellulose, , starch, crosslinked starch, polyethyleneimine, methoxypolyethylene glycol, ethoxypolyethylene glycol, polyethylene oxide, polyoxyethylene, polyoxypropylene, cellulose acetate, sodium alginate, N,N-diethylaminoacetate, block copolymers of polyoxyethylene and polyoxypropylene, polyvinyl pyrrolidone, polyoxyethylene X-lauryl ether wherein X is from 9 to 20, and polyoxyethylene sorbitan esters. The formulation is useful for the production of stable liposomes for delivery of cosmetics, drugs, enzymes, growth factors, hormones, interferons, interleukins, moisturizers, peptides, proteins, and steroids. A variety of administration techniques, e.g. oral, injection, topical, may be used, depending on the medicinally active ingredient.